Relay Therapeutics RLAY 深 沪
等待开盘 08-10 09:30:00 美东时间
19.77
+0.020
+0.10%
华盛通- 最 高20.26
- 今 开19.22
- 成交量 227.49万股
- 最 低 18.675
- 昨 收 19.75
- 总市值 215.49万
- 52周最高 20.79
- 市盈率 静 --
- 换手率 2087.10%
- 52周最低 3.31
- 委 比 -73.91%
- 总股本 0.00亿
- 历史最高 64.37
- 量 比 1.27
- 振 幅 8.03%
- 历史最低 1.10
- 每 手 1
- 风险率 4.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Relay Therapeutics Launches $175M Public Stock Offering
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that
05-20 04:04
Relay Therapeutics Q4 Earnings Assessment
Relay Therapeutics (NASDAQ:RLAY) announced its Q4 earnings on Thursday, Februar...
02-27 05:19
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
<p>Relay Therapeutics, Inc. announced the appointment of Dr. Claire Mazumdar to its Board of Directors. Dr. Mazumdar brings extensive experience in clinical-stage oncology and drug development, particularly in precision medicine. She previously founded Bicara Therapeutics and led business development at Rheos Medicines, collaborating with Roche Pharmaceuticals. With her expertise, she will support Relay Therapeutics in advancing its drug discovery efforts.</p>
2025-06-11 20:05
全球进展最快的AI药物又有新突破：Rentosertib二期数据在学术顶刊发表
AI制药公司英矽智能的在研药Rentosertib有了新突破。6月3日，Rentosertib的IIa期临床研究结果被刊登于全球顶尖学术期刊《自然·医学》（N...
2025-06-04 09:13
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Relay Therapeutics reported promising interim data for RLY-2608, showing a median progression-free survival (PFS) of 10.3 months overall and 11.0 months for second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data support the planned Phase 3 ReDiscover-2 study to begin mid-2025 and highlight RLY-2608's improved tolerability and efficacy compared to current treatments. Next-generation triplet combinations with atirmociclib and ribociclib are also being evaluated.
2025-06-02 11:00
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics (RLAY) announced its management will participate in two fireside chats in June: Jefferies Global Healthcare Conference on June 4 and Goldman Sachs Global Healthcare Conference on June 11. Both events will be live webcast on the company's website.
2025-05-29 20:05
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $18 to $19.
2024-09-16 19:14
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.
2024-09-12 00:22
